How To Use CPT Code 0701T

CPT 0701T describes the use of molecular fluorescent imaging to assess suspicious nevi for tissue changes and cell abnormalities. This article will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples.

1. What is CPT Code 0701T?

CPT 0701T can be used to describe the additional lesions assessed using molecular fluorescent imaging. This code is used when a provider applies a fluorescent peptide dye to biomarker protein-receptors in suspicious nevi and surrounding areas. The imager is then used to excite the dye and capture fluorescence to mark tissue undergoing changes from benign to abnormal. Analysis software may be used to assess the likelihood of tissue changes. It is important to note that this code is an add-on code and should be reported with an appropriate primary code, such as CPT 0700T for the first lesion.

2. Official Description

The official description of CPT code 0701T is: ‘Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure).’ This code is used to report the assessment of each additional lesion using molecular fluorescent imaging after the first lesion has been assessed.

3. Procedure

1. The provider applies a fluorescent peptide dye to biomarker protein-receptors in the suspicious nevus and surrounding area.
2. The imager is used to excite the dye and capture fluorescence to mark tissue undergoing changes from benign to abnormal.
3. Analysis software may be used to assess the likelihood of tissue changes based on mole characteristics, such as size, shape, and color.
4. This code applies to each additional lesion assessed using molecular fluorescent imaging after the first lesion.

4. Qualifying circumstances

Patients eligible to receive CPT 0701T services are those with suspicious nevi that require assessment for tissue changes and cell abnormalities. The provider must use molecular fluorescent imaging and apply a fluorescent peptide dye to biomarker protein-receptors in the suspicious nevus and surrounding area. This code is used to report each additional lesion assessed using molecular fluorescent imaging after the first lesion.

5. When to use CPT code 0701T

CPT code 0701T should be used when a provider assesses each additional lesion using molecular fluorescent imaging after the first lesion has been assessed. It is important to report this code in conjunction with an appropriate primary code, such as CPT 0700T for the first lesion. This code should not be reported without a primary code.

6. Documentation requirements

To support a claim for CPT 0701T, the provider must document the following information:

• Number of additional lesions assessed using molecular fluorescent imaging
• Details of the procedure, including the application of fluorescent peptide dye and use of the imager
• Analysis software used, if applicable
• Mole characteristics assessed, such as size, shape, and color
• Any tissue changes or abnormalities identified
• Signature of the provider performing the assessment

7. Billing guidelines

When billing for CPT 0701T, ensure that the procedure involves the assessment of each additional lesion using molecular fluorescent imaging. This code should be reported in addition to the primary code for the first lesion, such as CPT 0700T. Payers will not reimburse for CPT 0701T if it is reported without an appropriate primary code. It is important to follow the specific guidelines provided by the payer regarding the use of add-on codes.

8. Historical information

CPT 0701T was added to the Current Procedural Terminology system on January 1, 2022. There have been no updates to the code since its addition.

9. Examples

1. A dermatologist assesses a suspicious nevus on a patient’s arm using molecular fluorescent imaging and identifies tissue changes. The provider then assesses an additional suspicious nevus on the patient’s leg using the same imaging technique.
2. A plastic surgeon assesses a suspicious nevus on a patient’s face using molecular fluorescent imaging and determines that the tissue is undergoing abnormal changes. The provider then assesses an additional suspicious nevus on the patient’s back using the same imaging technique.
3. An oncologist assesses a suspicious nevus on a patient’s chest using molecular fluorescent imaging and identifies cell abnormalities. The provider then assesses an additional suspicious nevus on the patient’s abdomen using the same imaging technique.
4. A dermatologist assesses a suspicious nevus on a patient’s back using molecular fluorescent imaging and determines that the tissue is benign. The provider then assesses an additional suspicious nevus on the patient’s arm using the same imaging technique.
5. A plastic surgeon assesses a suspicious nevus on a patient’s leg using molecular fluorescent imaging and identifies tissue changes. The provider then assesses an additional suspicious nevus on the patient’s face using the same imaging technique.
6. An oncologist assesses a suspicious nevus on a patient’s abdomen using molecular fluorescent imaging and determines that the tissue is undergoing abnormal changes. The provider then assesses an additional suspicious nevus on the patient’s chest using the same imaging technique.
7. A dermatologist assesses a suspicious nevus on a patient’s arm using molecular fluorescent imaging and identifies cell abnormalities. The provider then assesses an additional suspicious nevus on the patient’s back using the same imaging technique.
8. A plastic surgeon assesses a suspicious nevus on a patient’s face using molecular fluorescent imaging and determines that the tissue is benign. The provider then assesses an additional suspicious nevus on the patient’s leg using the same imaging technique.
9. An oncologist assesses a suspicious nevus on a patient’s chest using molecular fluorescent imaging and identifies tissue changes. The provider then assesses an additional suspicious nevus on the patient’s abdomen using the same imaging technique.
10. A dermatologist assesses a suspicious nevus on a patient’s back using molecular fluorescent imaging and determines that the tissue is undergoing abnormal changes. The provider then assesses an additional suspicious nevus on the patient’s arm using the same imaging technique.